A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

Clinical trial NCT05735483 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT05735483
Sponsor: Eli Lilly and Company
Status: ENROLLING_BY_INVITATION
Phase: Phase 3
Study type: INTERVENTIONAL

Atopic Dermatitis Eczema

Start date: 2023-03-09
Primary completion: 2027-12-01
Enrollment: 333

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.